EPS for BioSyent Inc. (RX) Expected At $0.11 on March, 20

On March, 20 is expected BioSyent Inc. (CVE:RX)’s earnings report, RTT … Inc (TSE:ACB) CCO Cam Battley on Spin-out and Canopy Growth Corp …

On March, 20 is expected BioSyent Inc. (CVE:RX)’s earnings report, RTT reports. Analysts have expectation on stock’s EPS of $0.11. That’s up 10.00 % from last year’s $0.1 EPS. If V_RX’s EPS is $0.11 the profit will be $1.58M for 18.68 P/E. After $0.09 EPS report previous quarter, Wall Street now predicts 22.22 % EPS growth of BioSyent Inc.. Ticker’s shares touched $8.22 during the last trading session after 0.96% change.BioSyent Inc. is after having 0.00% since March 13, 2018. RX has 11,460 volume or 40.44% up from normal. RX underperformed the S&P 500 by 4.37%.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally.The company has $118.23 million market cap. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer.The P/E ratio is 21.75. The company’s products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Another two news for BioSyent Inc. (CVE:RX) were briefly announced by: Midasletter.com on August 18, 2018 with title “Aurora Cannabis Inc (TSE:ACB) CCO Cam Battley on Spin-out and Canopy Growth Corp – Constellation Brands Tie-up – Midas Letter”. The other Midasletter.com‘s article was titled “VIDEO: How Leviathan Cannabis Group Inc (CNSX:EPIC) Differentiates from the Pack – Midas Letter” and announced on July 25, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts